Linagliptin Orion
Linagliptin 5 mg — Film-coated tablet for type 2 diabetes mellitus
Quick Facts About Linagliptin Orion
Key Takeaways About Linagliptin Orion
- No renal dose adjustment needed: Unlike other DPP-4 inhibitors, linagliptin can be used at the same dose (5 mg) regardless of kidney function, making it ideal for patients with chronic kidney disease
- Weight-neutral treatment: Linagliptin does not cause weight gain, an important advantage for patients with type 2 diabetes who are often overweight
- Low risk of hypoglycemia: When used alone or with metformin, linagliptin has minimal risk of causing dangerously low blood sugar levels
- Proven cardiovascular safety: The CARMELINA trial confirmed that linagliptin does not increase the risk of heart attacks, strokes, or heart failure hospitalizations
- Once-daily dosing: Taken as a single 5 mg tablet once daily, with or without food, at any time of day
What Is Linagliptin Orion and What Is It Used For?
Linagliptin Orion is a prescription medicine containing linagliptin 5 mg, a DPP-4 inhibitor (dipeptidyl peptidase-4 inhibitor) used to treat type 2 diabetes mellitus in adults. It lowers blood sugar by boosting the body's incretin hormones, which stimulate insulin release after meals and reduce glucagon production.
Type 2 diabetes mellitus is a chronic metabolic condition affecting over 500 million people worldwide, according to the International Diabetes Federation. It occurs when the body either does not produce enough insulin or does not use insulin effectively, leading to persistently elevated blood glucose levels. Left untreated, high blood sugar can damage blood vessels, nerves, kidneys, eyes, and the heart over time.
Linagliptin Orion belongs to a class of medicines called DPP-4 inhibitors, also known as gliptins. The enzyme DPP-4 normally breaks down incretin hormones (GLP-1 and GIP) that are released from the gut after eating. By blocking DPP-4, linagliptin prevents the degradation of these hormones, allowing them to remain active for longer. The result is increased glucose-dependent insulin secretion from pancreatic beta cells and reduced glucagon release from alpha cells, leading to lower blood glucose levels after meals and during fasting.
A key advantage of linagliptin's mechanism is that insulin secretion is stimulated only when blood glucose is elevated. When glucose levels are normal or low, linagliptin does not push insulin release further, which explains its low risk of causing hypoglycemia when used alone or with metformin. This glucose-dependent mechanism makes linagliptin fundamentally different from sulfonylureas, which stimulate insulin release regardless of blood glucose levels.
Linagliptin Orion is indicated for type 2 diabetes in adults in the following settings:
- Monotherapy: When diet and exercise alone are not sufficient and metformin is inappropriate due to intolerance or contraindications (e.g., severe renal impairment)
- Dual combination therapy: In combination with metformin, a sulfonylurea, a thiazolidinedione (e.g., pioglitazone), or insulin, when these agents alone with diet and exercise do not provide adequate glycemic control
- Triple combination therapy: With metformin and a sulfonylurea, or with metformin and insulin, when dual therapy is insufficient
Linagliptin Orion is not used for type 1 diabetes or diabetic ketoacidosis. It is a generic version of the original brand Trajenta, containing the same active substance (linagliptin 5 mg) and manufactured according to the same quality standards required by the European Medicines Agency (EMA).
What Should You Know Before Taking Linagliptin Orion?
Before starting Linagliptin Orion, inform your doctor about all medical conditions, especially a history of pancreatitis, heart failure, or allergic reactions to DPP-4 inhibitors. Special caution is needed when combining linagliptin with sulfonylureas or insulin due to increased hypoglycemia risk.
Contraindications
Do not take Linagliptin Orion if you are allergic to linagliptin or any of the other ingredients in this medicine. Symptoms of a serious allergic reaction may include skin rash, raised red patches on the skin (hives), swelling of the face, lips, tongue, and throat that may cause difficulty breathing or swallowing. If you experience any of these symptoms, stop taking the medicine and seek emergency medical attention immediately.
Linagliptin Orion should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis, as it is not effective in these conditions. The incretin-based mechanism requires functioning pancreatic beta cells, which are largely destroyed in type 1 diabetes.
Warnings and Precautions
Talk to your doctor or pharmacist before taking Linagliptin Orion if any of the following applies to you:
- History of pancreatitis: Cases of acute pancreatitis have been reported in patients taking DPP-4 inhibitors. Symptoms include severe, persistent abdominal pain that may radiate to the back, sometimes accompanied by nausea and vomiting. If you experience these symptoms, stop taking the medicine and contact your doctor immediately. If pancreatitis is confirmed, linagliptin should not be restarted.
- Concomitant use with sulfonylureas or insulin: When linagliptin is used together with a sulfonylurea (e.g., glimepiride, glibenclamide) or insulin, the risk of hypoglycemia (low blood sugar) increases. Your doctor may reduce the dose of the sulfonylurea or insulin to minimize this risk.
- Skin reactions: Rare cases of bullous pemphigoid (a skin condition causing large, fluid-filled blisters) have been reported. If you develop blisters or skin erosions, discontinue the medicine and consult your doctor.
- Heart failure: Experience with linagliptin in patients with New York Heart Association (NYHA) functional class III-IV heart failure is limited. Use with caution in these patients.
Seek immediate medical attention if you experience severe, persistent upper abdominal pain (which may radiate to the back), nausea, or vomiting while taking Linagliptin Orion. These could be signs of pancreatitis, a potentially serious condition. Stop taking the medicine until your doctor advises you otherwise.
Pregnancy and Breastfeeding
Linagliptin Orion should not be used during pregnancy. There are limited data from the use of linagliptin in pregnant women. Animal studies have not shown direct harmful effects on reproductive function, but as a precautionary measure, this medicine should be avoided during pregnancy. If you are pregnant, think you might be pregnant, or are planning to have a baby, consult your doctor before taking this medicine. Your doctor will likely switch you to insulin for blood glucose control during pregnancy, as insulin is the preferred treatment for gestational diabetes management.
It is not known whether linagliptin passes into human breast milk. Animal studies have shown excretion of linagliptin in milk. A decision must be made whether to discontinue breastfeeding or to discontinue linagliptin therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. Do not use this medicine while breastfeeding without first consulting your doctor.
Driving and using machines: Linagliptin Orion has no or negligible effect on the ability to drive and use machines. However, when used in combination with a sulfonylurea or insulin, hypoglycemia may occur, which can impair concentration and reaction time. Patients should be advised to take precautions to avoid hypoglycemia while driving.
How Does Linagliptin Orion Interact with Other Drugs?
Linagliptin has relatively few clinically significant drug interactions. The most important interaction is with strong P-glycoprotein/CYP3A4 inducers such as rifampicin, which can reduce linagliptin's effectiveness. Combined use with sulfonylureas or insulin increases hypoglycemia risk and may require dose adjustment.
Linagliptin is primarily metabolized via the CYP3A4 enzyme system and is also a substrate of P-glycoprotein (P-gp). Unlike many other drugs, linagliptin does not significantly inhibit or induce these enzymes at therapeutic doses, which limits its potential for drug-drug interactions. However, certain medications can affect linagliptin levels or interact pharmacodynamically.
Major Interactions
| Drug | Interaction | Clinical Recommendation |
|---|---|---|
| Rifampicin | Strong CYP3A4/P-gp inducer. Reduces linagliptin exposure (AUC) by approximately 40%, potentially decreasing efficacy. | Combination not recommended. Consider alternative antidiabetic therapy or alternative antibiotic. |
| Sulfonylureas (glimepiride, glibenclamide, glipizide) | Pharmacodynamic interaction. Additive glucose-lowering effect increases risk of hypoglycemia. | Consider reducing sulfonylurea dose when initiating linagliptin. Monitor blood glucose frequently. |
| Insulin | Pharmacodynamic interaction. Additive glucose-lowering effect increases risk of hypoglycemia. | Consider reducing insulin dose when initiating linagliptin. Close blood glucose monitoring required. |
Minor Interactions
| Drug | Interaction | Clinical Recommendation |
|---|---|---|
| Ritonavir | Strong CYP3A4 inhibitor / P-gp inhibitor. Increases linagliptin exposure by approximately 2-fold, but no dose adjustment is generally needed. | No dose adjustment necessary. Monitor for increased side effects. |
| Carbamazepine, Phenobarbital, Phenytoin | Moderate CYP3A4/P-gp inducers. May modestly reduce linagliptin exposure. | Monitor glycemic control. No dose adjustment typically needed but consider if glucose control deteriorates. |
| Metformin | No pharmacokinetic interaction. Complementary mechanisms of action provide additive glucose-lowering effect. | Safe to combine. No dose adjustment for either drug needed. First-line combination for type 2 diabetes. |
| Warfarin | No clinically significant pharmacokinetic interaction observed in clinical studies. | No dose adjustment needed. Standard INR monitoring as usual. |
| Digoxin | No clinically significant interaction. Co-administration does not affect digoxin pharmacokinetics. | No dose adjustment needed for either drug. |
Linagliptin does not significantly affect the pharmacokinetics of metformin, glyburide, simvastatin, pioglitazone, warfarin, digoxin, or oral contraceptives. This favorable interaction profile is one of the advantages of linagliptin, particularly for patients with type 2 diabetes who typically take multiple medications for comorbid conditions such as hypertension, dyslipidemia, and cardiovascular disease.
What Is the Correct Dosage of Linagliptin Orion?
The recommended dose of Linagliptin Orion is 5 mg once daily, taken by mouth with or without food. No dose adjustment is required for renal impairment, hepatic impairment, or elderly patients. This is the same dose for all adult patients.
Linagliptin has one of the simplest dosing regimens among diabetes medications. The dose is 5 mg once daily for all adult patients, regardless of kidney function, liver function, age, or body weight. This uniform dosing eliminates the need for dose titration and simplifies diabetes management, particularly in patients with multiple comorbidities.
Adults
Standard Adult Dose
Dose: 5 mg once daily
Administration: Swallow the tablet whole with water. Can be taken with or without food, at any time of day. Choose a consistent time for best adherence.
Combination therapy: When added to metformin, continue the current metformin dose. When added to a sulfonylurea or insulin, a lower dose of the sulfonylurea or insulin may be needed to reduce the risk of hypoglycemia.
Children and Adolescents
Pediatric Use
Linagliptin Orion is not recommended for children and adolescents under 18 years of age. The safety and efficacy of linagliptin in pediatric patients have not been established. Type 2 diabetes in children is typically managed with lifestyle modifications and, when necessary, metformin or insulin.
Elderly Patients
Elderly Dose (65 years and older)
Dose: 5 mg once daily — no dose adjustment required.
Clinical trials included patients up to 80 years of age, and no age-related differences in safety or efficacy were observed. However, elderly patients may be more susceptible to hypoglycemia, especially when linagliptin is used in combination with a sulfonylurea or insulin. More frequent blood glucose monitoring may be appropriate.
Linagliptin is unique among DPP-4 inhibitors in that less than 5% is excreted renally. It is primarily eliminated via the enterohepatic system (bile and feces) as unchanged drug. Therefore, no dose adjustment is needed for any degree of renal impairment, including patients with end-stage renal disease (ESRD) on hemodialysis. This makes linagliptin a preferred choice for diabetic patients with chronic kidney disease (CKD), a common complication of diabetes.
Missed Dose
If you forget to take a dose of Linagliptin Orion, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the next one at your regular time. Do not take a double dose to make up for a forgotten dose. If you are unsure, ask your doctor or pharmacist for advice.
Overdose
In clinical trials, single doses of up to 600 mg linagliptin (120 times the recommended therapeutic dose) were well tolerated in healthy subjects, with no clinically meaningful adverse effects. If an overdose occurs, employ standard supportive measures as appropriate, such as removing unabsorbed material from the gastrointestinal tract, clinical monitoring, and instituting supportive care. Linagliptin is not expected to be dialyzable to a clinically meaningful degree due to its extensive tissue binding.
There is no specific antidote for linagliptin overdose. If you suspect you or someone else has taken too much Linagliptin Orion, contact your doctor, pharmacist, or poison control center immediately for guidance.
What Are the Side Effects of Linagliptin Orion?
Linagliptin is generally well tolerated. The most commonly reported side effects include nasopharyngitis (common cold), cough, and hypoglycemia (mainly when combined with sulfonylureas or insulin). Serious but rare side effects include pancreatitis, severe allergic reactions, and bullous pemphigoid.
Like all medicines, Linagliptin Orion can cause side effects, although not everybody gets them. The side effects listed below are based on data from clinical trials involving over 10,000 patients treated with linagliptin, as well as post-marketing surveillance data reported to regulatory agencies worldwide.
The frequencies are classified according to the following convention: very common (affects more than 1 in 10 people), common (affects 1 to 10 in 100 people), uncommon (affects 1 to 10 in 1,000 people), rare (affects 1 to 10 in 10,000 people), and very rare (affects fewer than 1 in 10,000 people).
Common Side Effects
Affects 1 to 10 in 100 people
- Nasopharyngitis (inflammation of the nose and throat, common cold symptoms)
- Cough
- Hypoglycemia (low blood sugar) — mainly when used with a sulfonylurea or insulin
- Increased blood lipase levels (usually without symptoms, detected in blood tests)
Uncommon Side Effects
Affects 1 to 10 in 1,000 people
- Hypersensitivity reactions (rash, urticaria/hives)
- Pancreatitis (inflammation of the pancreas — severe abdominal pain)
- Constipation
- Increased blood amylase levels
- Mouth ulceration (stomatitis)
Rare Side Effects
Affects 1 to 10 in 10,000 people
- Bullous pemphigoid (skin condition with large blisters)
- Angioedema (swelling of face, lips, tongue, or throat)
- Severe allergic reactions (anaphylaxis)
- Rhabdomyolysis (muscle breakdown — reported very rarely in post-marketing)
Linagliptin monotherapy (without sulfonylurea or insulin) has a hypoglycemia rate similar to placebo, meaning it very rarely causes low blood sugar when used alone or with metformin. This is because linagliptin's glucose-lowering effect is glucose-dependent: it only increases insulin secretion when blood sugar is elevated. When glucose levels normalize, the incretin-mediated insulin stimulus fades.
In the large cardiovascular outcomes trial CARMELINA, which enrolled 6,979 patients with type 2 diabetes and high cardiovascular and renal risk followed for a median of 2.2 years, the overall incidence of adverse events was comparable between linagliptin and placebo. There was no increased risk of pancreatitis, pancreatic cancer, or heart failure hospitalization compared to placebo.
Stop taking Linagliptin Orion and contact your doctor or go to the nearest emergency department immediately if you experience any of the following: severe persistent abdominal pain (possible pancreatitis), signs of a severe allergic reaction such as swelling of the face, lips, or throat with difficulty breathing, or large fluid-filled blisters on the skin (possible bullous pemphigoid).
Reporting side effects: If you experience any side effects, talk to your doctor or pharmacist. You can also report side effects directly to your national pharmacovigilance agency (e.g., the Yellow Card Scheme in the UK, MedWatch in the USA, or the corresponding agency in your country). By reporting side effects, you can help provide more information on the safety of this medicine.
How Should You Store Linagliptin Orion?
Store Linagliptin Orion at room temperature below 25°C (77°F) in the original packaging to protect from moisture. Keep out of the sight and reach of children. Do not use after the expiry date printed on the packaging.
Proper storage of medications is essential to maintain their effectiveness and safety. Linagliptin Orion tablets should be stored under the following conditions:
- Temperature: Store below 25°C (77°F). Do not freeze.
- Moisture protection: Store in the original blister packaging to protect from moisture. Linagliptin is sensitive to humidity, and exposure to moisture may affect the tablet's integrity.
- Light: No special light protection is needed, but storing in the original packaging is recommended.
- Children: Keep out of the sight and reach of children.
- Expiry date: Do not use this medicine after the expiry date stated on the blister and carton. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. Pharmaceutical waste disposal programs exist in many countries to ensure safe destruction of unused medications.
What Does Linagliptin Orion Contain?
Each Linagliptin Orion tablet contains 5 mg of the active substance linagliptin. The tablets also contain inactive ingredients (excipients) that help form the tablet and its protective film coating.
The active substance is linagliptin. Each film-coated tablet contains 5 mg of linagliptin.
Excipients (inactive ingredients):
- Tablet core: Mannitol, pregelatinized starch (maize), maize starch, copovidone, magnesium stearate
- Film coating: Hypromellose, titanium dioxide (E171), talc, macrogol 6000, iron oxide red (E172)
The film-coated tablets are light pink, round, biconvex, with a diameter of approximately 8 mm. They are available in blister packs containing 10, 14, 28, 30, 56, 60, 84, 90, 98, or 100 tablets. Not all pack sizes may be marketed in your country.
If you have a known allergy or intolerance to any of the excipients listed above (for example, mannitol or certain colorants), inform your doctor or pharmacist before taking this medicine.
Frequently Asked Questions About Linagliptin Orion
Linagliptin Orion is used to treat type 2 diabetes mellitus in adults. It works by inhibiting the DPP-4 enzyme, which increases the body's own incretin hormones (GLP-1 and GIP) that stimulate insulin release and suppress glucagon. It is used as monotherapy when metformin is not tolerated, or in combination with metformin, sulfonylureas, thiazolidinediones, or insulin when these agents alone do not provide adequate blood glucose control.
No, linagliptin is considered weight-neutral. Clinical trials have consistently shown that linagliptin does not cause significant weight gain or weight loss. This is an important advantage over some other diabetes medications such as sulfonylureas, thiazolidinediones, and insulin, which can cause weight gain. For patients with type 2 diabetes who are already overweight or obese, a weight-neutral medication is often preferred.
No. Linagliptin is unique among DPP-4 inhibitors because it does not require dose adjustment for any degree of renal impairment, including patients on hemodialysis. Less than 5% of the drug is excreted through the kidneys; it is primarily eliminated via the enterohepatic system (through bile and feces). This makes it a particularly suitable choice for diabetic patients with chronic kidney disease, which is a very common complication of long-standing type 2 diabetes.
When used alone or with metformin, linagliptin has a very low risk of hypoglycemia — comparable to placebo. This is because it only stimulates insulin release when blood glucose levels are elevated (glucose-dependent mechanism). However, when combined with a sulfonylurea or insulin, the risk of hypoglycemia increases significantly. In these combinations, your doctor may need to reduce the dose of the sulfonylurea or insulin to prevent low blood sugar episodes.
Linagliptin Orion and Trajenta contain the same active ingredient (linagliptin 5 mg) and work identically. Linagliptin Orion is a generic version manufactured by Orion Pharma, while Trajenta is the original brand-name product developed by Boehringer Ingelheim. Generic medicines must meet the same quality, safety, and bioequivalence standards as the original product, as required by the European Medicines Agency (EMA) and other regulatory authorities.
Yes. The CARMELINA cardiovascular outcomes trial, which enrolled nearly 7,000 patients with type 2 diabetes and high cardiovascular and renal risk, demonstrated that linagliptin does not increase the risk of major adverse cardiovascular events (MACE — cardiovascular death, non-fatal heart attack, or non-fatal stroke) compared to placebo. Importantly, it also showed no increase in heart failure hospitalizations, which has been a concern with some other DPP-4 inhibitors. The CAROLINA trial further showed non-inferiority to glimepiride for cardiovascular outcomes.
References
All medical information on this page is based on peer-reviewed research, international clinical guidelines, and regulatory documents. The following sources have been used:
- European Medicines Agency (EMA). Trajenta (linagliptin) — Summary of Product Characteristics. EMA/CHMP. Last updated 2024. Available at: www.ema.europa.eu
- Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79. doi:10.1001/jama.2018.18269
- Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155-1166. doi:10.1001/jama.2019.13772
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1). Available at: diabetesjournals.org/care
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. doi:10.2337/dci22-0034
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List, 2023. Geneva: WHO; 2023.
- Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2020;16(11):642-653. doi:10.1038/s41574-020-0399-8
- U.S. Food and Drug Administration (FDA). Tradjenta (linagliptin) tablets — Prescribing Information. Last revised 2024. Available at: www.fda.gov
- British National Formulary (BNF). Linagliptin. NICE. Updated 2024. Available at: bnf.nice.org.uk
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with specializations in endocrinology, clinical pharmacology, and internal medicine. Our team follows international evidence-based guidelines (ADA, EASD, WHO, EMA, FDA) and the GRADE framework for evaluating the quality of medical evidence.
iMedic Medical Editorial Team — Specialists in endocrinology and clinical pharmacology with documented academic background and clinical experience in diabetes management.
iMedic Medical Review Board — Independent panel of board-certified physicians who review all content according to international guidelines (ADA/EASD Consensus, WHO Essential Medicines, EMA/FDA regulatory data).
Evidence standard: All medical claims in this article are supported by Level 1A evidence (systematic reviews and meta-analyses of randomized controlled trials) where available, or Level 1B evidence (individual RCTs). The CARMELINA and CAROLINA cardiovascular outcomes trials provide the highest level of evidence for linagliptin's cardiovascular safety.
Editorial independence: iMedic receives no funding from pharmaceutical companies. All content is independently produced and reviewed without commercial influence.